A potentially more effective treatment for HER2 mutant metastatic breast cancer

Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor College of Medicine investigated whether different HER2 mutations drove different responses to therapy. They were able to identify a mutation that conferred therapeutic resistance and promoted metastatic behavior.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup